NIMA related kinase 2Genealiases: HsPK21 · NEK2A · NLK1 · PPP1R111 · RP67
Q-omics provides the consensus-scored NEK2 profile across patient tissues and cancer cell-line models. NEK2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NEK2 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, NEK2 RNA expression shows 25,892 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where NEK2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEK2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEK2 survival associations across molecular data types. NEK2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEK2 RNA expression–survival associations across cancer types. High NEK2 expression shows unfavorable associations in ACC, MESO, KIRP, KICH, LIHC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NEK2 RNA expression.
This table summarizes NEK2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NEK2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEK2 shows higher tumor expression in HNSC, BLCA, LUAD, KIRP, COAD and KIRC. The HNSC box plot shows higher NEK2 RNA expression in tumor versus normal tissue (log2 FC = +2.148, t-test p < 0.001).
This table shows molecular features associated with NEK2 in patient tissues and cancer cell lines. In patient samples, NEK2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NEK2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
